Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd Ordinary Shares (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 753,775
  • Shares Outstanding, K 13,750
  • Annual Sales, $ 8,160 K
  • Annual Income, $ -20,000 K
  • 36-Month Beta N/A
  • Price/Sales 88.36
  • Price/Cash Flow N/A
  • Price/Book 6.15

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.13 +0.56%
on 06/22/18
62.78 -16.50%
on 05/23/18
-9.47 (-15.30%)
since 05/22/18
3-Month
47.38 +10.64%
on 04/02/18
69.57 -24.65%
on 05/21/18
-1.88 (-3.46%)
since 03/22/18
52-Week
15.56 +236.89%
on 06/23/17
69.57 -24.65%
on 05/21/18
+34.75 (+196.66%)
since 06/22/17

Most Recent Stories

More News
UroGen Pharma's Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie...

URGN : 52.42 (-4.38%)
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mesoblast Limited (NASDAQ:MESO),...

MESO : 5.86 (-3.30%)
URGN : 52.42 (-4.38%)
CSGP : 412.09 (-0.72%)
TTGT : 29.14 (+1.08%)
ANCX : 30.19 (+0.40%)
SINA : 88.81 (+0.92%)
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that Stephen Mullennix, UroGen's Chief...

URGN : 52.42 (-4.38%)
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron...

URGN : 52.42 (-4.38%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 52.42 (-4.38%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 52.42 (-4.38%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 52.42 (-4.38%)
ACIA : 33.33 (+0.39%)
TCPC : 14.40 (-0.21%)
DORM : 72.23 (+0.65%)
ACGL : 26.48 (+0.46%)
CONE : 57.85 (-0.31%)
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis

NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis...

URGN : 52.42 (-4.38%)
NVS : 75.06 (+1.46%)
UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC)

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced a new data...

URGN : 52.42 (-4.38%)
Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Prothena Corporation PLC (NASDAQ:PRTA),...

WLTW : 154.16 (+1.15%)
FLWS : 12.90 (-0.77%)
URGN : 52.42 (-4.38%)
FBNK : 31.30 (-0.79%)
PRTA : 15.67 (+4.19%)
MFG : 3.40 (+0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade URGN with:

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

2nd Resistance Point 56.01
1st Resistance Point 54.22
Last Price 52.42
1st Support Level 51.38
2nd Support Level 50.33

See More

52-Week High 69.57
Last Price 52.42
Fibonacci 61.8% 48.94
Fibonacci 50% 42.56
Fibonacci 38.2% 36.19
52-Week Low 15.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar